Clinical characteristics of patients with severe sepsis and septic shock in relation to bacterial virulence of beta-hemolytic *Streptococcus* and *Streptococcus pneumoniae*

Toru Hifumi,1 Seitaro Fujishima,2 Kimiko Ubukata,2 Akiyoshi Hagiwara,3 Toshikazu Abe,4 Hiroshi Ogura,5 Atsushi Shiraiishi,6 Shigeki Kushimoto,6 Daizoh Saitoh,8 Toshihiko Mayumi,9 Hiroto Ikeda,10 Masashi Ueyama,11 Yasuhiro Otomo,12 Kohji Okamoto,13 Yutaka Umemura,5 Joji Kotani,14 Yuichiro Sakamoto,15 Junichi Sasaki,16 Yasukazu Shiino,17 Shin-ichiro Shiraishi,18 Kiyotsugu Takuma,19 Takehiko Tarui,20 Ryosuke Tsuruta,21 Taka-aki Nakada,22 Kazuma Yamakawa,23 Tomohiko Masuno,24 Naoshi Takeyama,25 Norio Yamashita,26 Satoshi Fujimi,23 Satoshi Gando,27 and on behalf of the JAAM FORECAST group

1Department of Emergency and Critical Care Medicine, St. Luke’s International Hospital, Emergency Medical Center, 2Center for General Medicine Education, School of Medicine, Keio University, 3Emergency Medicine, Center Hospital of the National Center for Global Health and Medicine, 4Department of General Medicine, Juntendo University, Tokyo, Japan, 5Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Suita, Japan, 6Emergency Department, Kameda Medical Center, Kamogawa, Japan, 7Division of Emergency and Critical Care Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan, 8Division of Traumatology, Research Institute, National Defense Medical College, Saitama, Japan, 9Department of Emergency Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 10Department of Emergency Medicine, Teikyo University School of Medicine, Tokyo, Japan, 11Department of Trauma, Critical Care Medicine, and Burn Center, Japan Community Healthcare Organization, Chukyo Hospital, Nagoya, Japan, 12Trauma and Acute Critical Care Medical Center, Medical Hospital, Tokyo Medical and Dental University, Tokyo, Japan, 13Department of Surgery, Center for Gastroenterology and Liver Disease, Kitakyushu City Yahata Hospital, Kitakyushu, Japan, 14Department of Emergency, Disaster and Critical Care Medicine, Hyogo College of Medicine, Nishinomiya, Japan, 15Emergency and Critical Care Medicine, Saga University Hospital, Saga, Japan, 16Department of Emergency and Critical Care Medicine, Keio University School of Medicine, Tokyo, Japan, 17Department of Acute Medicine, Kawasaki Medical School, Kurashiki, Japan, 18Department of Emergency and Critical Care Medicine, Aizu Chuo Hospital, Fukushima, Japan, 19Emergency and Critical Care Center, Kawasaki Municipal Kawasaki Hospital, Kawasaki, Japan, 20Department of Trauma and Critical Care Medicine, Kyorin University School of Medicine, Mitaka, Japan, 21Advanced Medical Emergency and Critical Care Center, Yamanashi University Hospital, Ube, Japan, 22Department of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Chiba, Japan, 23Division of Trauma and Surgical Critical Care, Osaka General Medical Center, Osaka, Japan, 24Department of Emergency and Critical Care Medicine, Nippon Medical School, Tokyo, Japan, 25Advanced Critical Care Center, Aichi Medical University Hospital, Nagakute, Japan, 26Advanced Emergency Medical Service Center, Kurume University Hospital, Kurume, Japan, and 27Division of Acute and Critical Care Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan

**Aim:** Combined detailed analysis of patient characteristics and treatment as well as bacterial virulence factors, which all play a central role in the cause of infections leading to severe illness, has not been reported. We aimed to describe the patient characteristics

*Corresponding: Toru Hifumi, MD, PhD, Department of Emergency and Critical Care Medicine, St. Luke’s International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo 104-8560, Japan. E-mail: hifumitoru@gmail.com.
Received 21 Jan, 2020; accepted 12 Apr, 2020
Funding information
This study was supported by the Japanese Association for Acute Medicine (2014-01).
INTRODUCTION

In the past two decades, the mortality of severe sepsis has decreased considerably from 35% to less than 20%, likely due to the global acts against sepsis targeting all identified bacteria in the Surviving Sepsis Campaign Guidelines. However, this universal approach is not always sufficient to benefit patients infected with specific pathogens, such as Streptococcus pneumoniae, and beta-hemolytic Streptococcus, which induce a high mortality rate. To further improve these patients’ outcomes, focusing on the specific bacteria responsible for sepsis is a reasonable first step to establish an individualized therapeutic strategy.

Bacterial virulence is “the ability” to enter into a host, survive at host sites, and damage host cells, and plays a central role in the cause of infections, leading to severe sepsis and septic shock. Although prognostic factors of S. pneumoniae and beta-hemolytic Streptococcus sepsis have been examined in several studies, a combined detailed analysis of patient characteristics, treatment (3-h bundle of sepsis care in the Surviving Sepsis Campaign Guidelines 2016), and bacterial virulence factors has not been reported. Recently, a published study including approximately 50,000 patients concluded that a 3-h bundle of sepsis care was associated with lower risk-adjusted in-hospital mortality. However, in this study, 3-h bundle of sepsis care completion was not significantly associated with in-hospital mortality in Gram-positive bacteremia (odds ratio, 1.01 [confidence interval, 0.98–1.05]). Therefore, it is imperative to examine the baseline characteristics, treatment (3-h bundle), and virulence factors in Gram-positive bacteremia such as S. pneumoniae and beta-hemolytic Streptococcus.

Thus, the current investigation was the first study to describe the characteristics, treatment (3-h bundle), and outcomes of patients with severe sepsis and septic shock in relation to bacterial virulence of S. pneumoniae and beta-hemolytic Streptococcus.

METHODS

Study design

This is one of the primary investigations of the Focused Outcomes Research in Emergency Care in Acute Respiratory Distress Syndrome, Sepsis and Trauma (FORECAST) study, a multicenter, prospective cohort study of patients infected by S. pneumoniae and beta-hemolytic Streptococcus with severe sepsis and septic shock. It was undertaken in 59 intensive care units from January 2016 to March 2017 in Japan. Each hospital had a microbiology laboratory. Streptococcus pneumoniae and beta-hemolytic Streptococcus isolates from sterile clinical samples such as blood, cerebrospinal fluid, pleural effusion, and joint fluid were sent promptly from each clinical laboratory to Keio University School, Department of Infectious Diseases. Laboratory technicians carried out this task in most hospitals; however, emergency physicians were required to do this in some hospitals. The laboratory of Keio University School, Department of Infectious Disease has sufficient experience of current analysis with quality control; the details of the sampling, preservation, and analysis for the examination of virulence factors in individual bacteria were previously reported. The results were promptly sent back to the hospitals from the laboratory of Keio University School, Department of Infectious Disease by e-mail from the chief investigator for clinical use.

The study protocol was reviewed and approved by the ethics committee of all institutes in the Japanese Association for Acute Medicine.
for Acute Medicine (JAAM) FORECAST sepsis study groups, Japan. Written informed consent was obtained from each patient or their legally authorized representative based on the decisions made by the local ethics committee, as appropriate. The study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR ID: UMIN000019702).

Study participants and inclusion criteria

Adult patients (≥16 years) with severe sepsis or septic shock based on sepsis-2 criteria were included in the FORECAST study. We included patients aged 16 years or older who were diagnosed with S. pneumoniae and beta-hemolytic Streptococcus sepsis. Both S. pneumoniae and beta-hemolytic Streptococcus were selected, combined, and analyzed as a whole (i.e., representative of Streptococcus), because they are similar species and several virulence factors are found across streptococcal species boundaries. Patients with unknown virulence (i.e., detailed examination of virulence factor was not performed because isolates were not sent to the laboratory of Keio University School, Department of Infectious Diseases) were excluded.

Definitions

The Charlson comorbidity index (CCI) is a widely used comorbidity index. Comorbid conditions with a weight of 1 include myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, ulcer disease, mild liver disease, and diabetes mellitus. Diabetes mellitus along with end-organ damage, any tumor, leukemia, and lymphoma have a weight of 2. Moderate or severe liver disease have a weight of 3. Metastatic solid tumors and AIDS have a weight of 6. The total score is calculated by adding the weights.

The presence of systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, or septic shock was defined according to the definitions of the American College of Chest Physicians/Society of Critical Care Medicine consensus conference statement and its 2003 revision. Illness severity was evaluated with the Sequential Organ Failure Assessment (SOFA) score. The diagnosis of disseminated intravascular coagulation (DIC) was made according to the JAAM DIC diagnostic criteria, with a total score of 4 or more establishing a diagnosis of DIC. Overt DIC was defined and modified according to the International Society of Thrombosis and Hemostasis criteria. Overt DIC was diagnosed when the sum of scores was 5 points or more.

Data sampling

The following data were collected: age, gender, presence of septic shock, location before intensive care unit, primary infection site, co-infection, CCI, vital signs on admission, laboratory data, SIRS score, DIC score, SOFA score, Acute Physiology and Chronic Health Evaluation II (APACHE-II) score, completion and details of a 3-h bundle, 28-day survival, and in-hospital mortality.

High-virulence factor

Bacterial virulence plays a key role in the establishment of bacterial infection; S. pneumoniae capsular types and the M protein gene sequence in beta-hemolytic Streptococcus are well-known virulence factors. We defined high-virulence factors in the current study based on the previously reported studies as follows:

Streptococcus pneumonia

Serotype 3, 31, 11A, 35F, and 17F (serotype 3 is a mucoid type, and is associated with serious infections that can lead to fatalities. Because serotype 31, 11A, 35F, and 17F reported higher mortality rates compared to serotype 3, we determined high-virulence factors as serotype 3, 31, 11A, 35F, and 17F in the current study.

Beta-hemolytic Streptococcus

Streptococcus pyogenes (group A streptococcus [GAS]); emm 1 (emm 1 has the sic gene that inhibits complement-dependent bacteriolysis).

Streptococcus agalactiae (group B streptococcus [GBS]); III (serotype III is the most common serotype in meningitis. Because the clonal complex 17, sequence type 17 strains are known to be highly virulent, and only included in serotype III, we determined high-virulence factor as serotype III in the current study).

Streptococcus dysgalactiae ssp. equisimilis (SDSE); emm typing pattern: stG 6792 (stG 6792 is the most common typing pattern in invasive SDSE infection).

Study end-points

The primary aim of the study was to describe clinical characteristics of patients (patient characteristics, treatment [3-h bundle], and outcome) with severe sepsis and septic shock between high and normal bacterial virulence of S. pneumoniae and beta-hemolytic Streptococcus.
Statistical analysis

Baseline characteristics were summarized for participants using descriptive statistics. Included patients were divided into two categories based on the virulence factor, high and normal. The distribution of each variable was compared between the two groups defined by the virulence factor (high vs. normal) using the Mann-Whitney U-test or Fisher’s exact test, depending on variables. Cox proportional hazards regression model of 28-day mortality was used to adjust covariates (CCI, completion of a 3-h bundle, and bacterial virulence factor). All statistical analyses were undertaken using IBM SPSS version 20.0J (IBM, Armonk, NY, USA) and STATA Data Analysis and Statistical Software (version 15.0; StataCorp, College Station, TX, USA). A two-sided P-value < 0.05 was considered statistically significant.

RESULTS

Demographic factors and patient characteristics, treatment, and outcome of all study patients

Of 1,184 SEPSIS patients enrolled in the JAAM FORECAST study registries, 124 met the inclusion criteria. Of these, 62 patients were excluded due to undetermined virulence. The remaining 62 patients were included in the current study (29 cases with *S. pneumoniae* sepsis and 33 with beta-hemolytic *Streptococcus*). Included patients were divided into two categories based on the virulence factor, high (*n* = 21) and normal (*n* = 41, Fig. 1).

The patient age ranged from 33 to 95 years (median, 71 years). Median CCI was 1, and initial SOFA score was 7 (5–11) (median [interquartile range]); 24.1% of patients were infected with bacteria with high virulence (Table 1). In-hospital mortality was 27.1% (*n* = 16), and 28-day survival was 76.3% (*n* = 45). Forty-one cases (67.2%) completed a 3-h bundle (Table S1).

Comparison of baseline characteristics between normal and high virulence groups

There was no difference in age, gender, rate of septic shock, infection site, or CCI between normal and high virulence factors (Table 2). Illness severity scores such as SIRS, DIC (JAAM), DIC (ISTH), SOFA score, and APACHE-II were not notably different between the high-virulence group and the normal-virulence group.

Comparison of treatment (3-h bundle) between normal and high virulence groups

Completion of a 3-h bundle was not statistically different between the normal-virulence group and the high-virulence group (77.5% versus 52.4%; *P* = 0.11). Completion rates of each component of the 3-h bundle, such as serum lactate obtainment, broad-spectrum antibiotic treatment, blood cultures obtained before broad-spectrum antibiotic treatment, and 30 mg/kg crystalloid fluid bolus treatment, were relatively higher in the normal-virulence group than in the high-virulence group (Table S2).

Comparison of outcome between virulence factors of normal and high groups

The risk of 28-day mortality was significantly higher for the high-virulence group compared to the normal-virulence group when adjusted for CCI and completion of a 3-h bundle (Cox proportional hazards regression analysis, hazard ratio 3.848; 95% confidence interval, 1.108–13.370; *P* = 0.034) (Table 3, Fig. S1).

DISCUSSION

In the current study, approximately one-quarter of severe sepsis and septic shock patients with *S. pneumoniae* and beta-hemolytic *Streptococcus* were infected with high-virulence bacteria. Risk of 28-day mortality was significantly higher for high-virulence compared to normal-virulence bacteria when adjusted for patient characteristics (CCI) and treatment (completion of a 3-h bundle).

Hanada et al. examined 506 Japanese adults with invasive pneumococcus disease (IPD), and found that host factors (age ≥ 80 years and underlying liver disease) and
bacterial virulence in Streptococcus pneumoniae and beta-hemolytic Streptococcus sepsis. Takahashi et al. \(^{23}\) examined clinical aspects in 231 patients with SDSE, 82 with GAS, and 123 with GBS, but treatment factors were not included in the analysis. In the current study, we showed the association between bacterial virulence and patient characteristics, treatment, and outcomes for patients with \(S.\) pneumoniae and beta-hemolytic Streptococcus sepsis.

There are no universal definitions for bacterial virulence;\(^5\) therefore, we defined high-virulence bacteria in the current study based on previous reports.\(^3,7,8,10\) Virulence was particularly determined by \(emm\) typing in GAS, and serotype in \(S.\) pneumoniae and GBS.\(^7,8\) whereas the rate of \(S.\) pneumoniae, GAS, and GBS between the two subgroups (high-virulence and normal-virulence subgroups) was not different. Although a significant difference was not observed, completion of a 3-h bundle was relatively higher in the normal-virulence group than in the high-virulence group (77.5% versus 53.3%; \(P = 0.11\)). Thus, we adjusted the covariates such as CCI and completion of a 3-h bundle, and the risk of 28-day mortality was significantly higher for patients with high-virulence compared to normal-virulence bacteria.

Approximately one-third of severe sepsis and septic shock with \(S.\) pneumoniae and beta-hemolytic Streptococcus occurred in patients infected with high-virulence bacteria who, thus, experienced higher mortality. In the era of increasing antibiotic resistance and decreasing antibiotic drug development, it is crucial that targeting virulence becomes an attractive therapeutic strategy, as Webb and Kahler proposed.\(^5\) Our study could contribute to the development of

### Table 1. Baseline characteristics of study patients with severe sepsis and septic shock (Continued)

| Characteristics                                      | Median (IQR) |
|------------------------------------------------------|--------------|
| APACHE-II                                            | 22 (17–27)   |
| In-hospital mortality                                | 16 (27.1)    |

Data are shown as median (interquartile range) or \(n\) (%). Missing data: infection site = 11, Glasgow Coma Scale (GCS) = 1, systolic blood pressure (SBP) = 2, respiratory rate (RR) = 1, lactate = 1, glucose = 1, C-reactive protein (CRP) = 1, base excess (BE) = 2, albumin (Alb) = 1, systemic inflammatory response syndrome (SIRS) = 3, bilirubin = 1, creatinine = 1, disseminated intravascular coagulation (DIC) (Japanese Association for Acute Medicine [JAAM]) = 9, DIC (International Society on Thrombosis and Haemostasis [ISTH]) = 12, Sequential Organ Failure Assessment (SOFA) score = 8, central nervous system = 1, pulmonary = 4, cardiovascular = 1, hepatic = 1, renal = 7, Acute Physiology and Chronic Health Evaluation II (APACHE-II) = 16, in-hospital mortality = 3. ER, emergency room; ICU, intensive care unit; STI, soft tissue infection.
Table 2. Comparison of characteristics between virulence factors (normal vs. high) in patients with severe sepsis and septic shock

| Characteristics                                      | Normal virulence  | High virulence  | P-value |
|------------------------------------------------------|-------------------|-----------------|---------|
|                                                      | (N = 41)          | (N = 21)        |         |
| Age, (years)                                         | 71 (65–78)        | 75 (63–81)      | 0.566   |
| Gender (male)                                        | 25 (61.0%)        | 18 (69.4%)      | 0.079   |
| Septic shock†                                        | 14 (34.2%)        | 12 (57.1%)      | 0.110   |
| Location before ICU (prior location)                 |                   |                 | 0.858   |
| ER                                                   | 27 (62.5%)        | 12 (57.1%)      |         |
| Other                                                | 14 (35.0%)        | 8 (38.1%)       |         |
| ICU                                                  | 1 (2.5%)          | 1 (4.8%)        |         |
| Bacteria                                             |                   |                 | 0.423   |
| *Streptococcus pneumoniae*                           | 21 (51.2%)        | 8 (38.1%)       |         |
| Beta-hemolytic *Streptococcus*                       | 20 (48.8%)        | 13 (61.9%)      |         |
| Infection site                                       |                   |                 | 0.064   |
| Abdomen                                              | 1 (2.4%)          | 0 (0%)          |         |
| Lung                                                 | 15 (36.6%)        | 8 (38.1%)       |         |
| Skin/STI                                             | 14 (34.2%)        | 9 (42.9%)       |         |
| Infectious endocarditis                              | 1 (2.4%)          | 1 (4.8%)        |         |
| Others                                               | 4 (9.8%)          | 2 (9.5%)        |         |
| Central nervous system                               | 5 (12.2%)         | 0 (0%)          |         |
| Co-infection                                         | 6 (14.6%)         | 0 (0%)          | 0.321   |
| Charlson comorbidity index                           | 1 (0–2)           | 1 (0–2)         | 0.811   |
| GCS                                                  | 14 (10–15)        | 15 (13–15)      | 0.283   |
| SBP (mmHg)                                           | 118 (94–143)      | 109 (91–139)    | 0.467   |
| RR (l/min)                                           | 25 (22–30)        | 29 (21–38)      | 0.548   |
| Lactate (mmol/L)                                     | 3.1 (2.1–4.9)     | 3.8 (2.3–5.7)   | 0.919   |
| Glucose (mg/dL)                                      | 149 (111–202)     | 122 (99–137)    | 0.048   |
| CRP (mg/dL)                                          | 25.9 (12.3–33.2)  | 29.8 (17.1–39.3)| 0.104   |
| BE                                                   | –3.5 (–5.7 to 0.4)| –5.8 (–10.1 to –3.3)| 0.051   |
| Alb (g/dL)                                           | 2.9 (2.3–3.4)     | 2.6 (2.3–3.0)   | 0.488   |
| SIRS                                                 | 3 (2–4)           | 3 (3–4)         | 0.407   |
| Bilirubin                                            | 0.8 (0.7–1.2)     | 1.3 (0.7–2.1)   | 0.113   |
| Creatinine                                           | 1.4 (1.0–2.2)     | 1.7 (1.5–2.6)   | 0.128   |
| DIC (JAAM)                                           | 4 (2–6)           | 4 (3–5)         | 0.861   |
| DIC (ISTH)                                           | 3 (1–5)           | 3 (1–4)         | 0.574   |
| SOFA score                                           | 7 (5–10)          | 9 (7–13)        | 0.081   |
| Central nervous system                               | 1 (0–2)           | 0 (0–2)         | 0.283   |
| Pulmonary                                            | 2 (1–2)           | 2 (1–2)         | 1.000   |
| Cardiovascular                                       | 1 (0–4)           | 4 (0–4)         | 0.204   |
| Hepatic                                              | 0 (0–1)           | 1 (0–2)         | 0.065   |
| Renal                                                | 1 (0–2)           | 2 (1–3)         | 0.101   |
| Hematological                                        | 1 (0–2)           | 1 (1–2)         | 0.451   |
| APACHE-II                                            | 22 (17–29)        | 21 (17–26)      | 0.553   |

Missing data: normal virulence, infection site = 9, Glasgow Coma Scale (GCS) = 1, systolic blood pressure (SBP) = 1, respiratory rate (RR) = 1, lactate = 1, glucose = 1, C-reactive protein (CRP) = 1, base excess (BE) = 2, albumin (Alb) = 1, systemic inflammatory response syndrome (SIRS) = 3, bilirubin = 1, creatinine = 1, disseminated intravascular coagulation (DIC) (Japanese Association for Acute Medicine (JAAM)) = 9, DIC (International Society on Thrombosis and Haemostasis (ISTH)) = 9, Sequential Organ Failure Assessment (SOFA) score = 5, central nervous system = 1, pulmonary = 2, cardiovascular = 1, hepatic = 1, renal = 5, Acute Physiology and Chronic Health Evaluation II (APACHE-II) = 12; high virulence, infection site = 2, SBP = 1, lactate = 1, DIC (ISTH) = 3, SOFA score = 3, pulmonary = 2, renal = 2, (APACHE-II) = 4.

ER, emergency room; ICU, intensive care unit; STI, soft tissue infection.

†Septic shock or lactate >4 mmol/L.
Table 3. Prognostic factors of 28-day mortality in patients with severe sepsis and septic shock, Cox’s proportional hazards regression analysis

| Factor                        | HR    | 95% CI       | P-value |
|-------------------------------|-------|--------------|---------|
| Virulence (high versus normal)| 3.849 | 1.108–13.370 | 0.034   |
| Charlson comorbidity index    | 1.083 | 0.730–1.609  | 0.689   |
| Completion of a 3-h bundle     | 1.277 | 0.368–4.436  | 0.700   |

CI, confirmation interval; HR, hazard ratio.

antibody treatments against bacterial virulence in *S. pneumoniae* and beta-hemolytic *Streptococcus* sepsis.

This study has several limitations. First, due to the small number of patients included in the analysis, *S. pneumoniae* and beta-hemolytic *Streptococcus* could not be examined independently. This might have caused the heterogeneity in the study populations. Thus, further study with larger populations with each pathogen should be undertaken to examine the hypothesis in the current study. However, *S. pneumoniae* and beta-hemolytic *Streptococcus* were analyzed as one category because several virulence factors in those bacteria are found across streptococcal species boundaries. Second, a detailed examination of virulence factors was not carried out in half of the cases; therefore, selection bias would occur. Emergency physicians, not laboratory technicians, were required to send clinical samples to Keio University in some hospitals. This seems to be the main reason for low numbers of cases submitted. Prospective studies with detailed examination of virulence factors for all eligible cases are required. Third, facility factors were not examined due to the unavailability of the dataset in the current study. This might have greatly affected the outcome. Finally, pneumococcal vaccination status was not obtained.

CONCLUSIONS

THE RISK OF 28-day mortality was significantly higher in patients with severe sepsis and septic shock infected with high-virulence compared to normal-virulence bacteria when adjusted for patient characteristics (CCI) and treatment (completion of a 3-h bundle).

ACKNOWLEDGMENT

WE THANK THE JAAM FORECAST Study Group (email: jaam-6@bz04.plala.or.jp) for their contribution to this study. This study was supported by JAAM (2014-01).

DISCLOSURE

Approval of the research protocol: The study protocol was reviewed and approved by the ethics committee of all participating institutes in the JAAM study group, Japan (IRB No. 015-0021 on Hokkaido University, the representative for FORECAST).

Informed consent: N/A.

Registry and the registration no. of the study/trial: The University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR ID: UMIN000019702), Date of registration: 11/09/2015, https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022760

Animal studies: N/A.

Conflict of interest: Dr. Seitaro Fujishima reports personal fees from Asahi Kasei Japan and Takeda Pharmaceutical, and grants from Chugai Pharmaceuticals, Daiichi-Sankyo, Otsuka Pharmaceutical, Pfizer, Astellas Pharma, Shionogi, and Teijin Pharma, outside the submitted work. Dr. Satoshi Gando reports personal fees from Asahi Kasei Japan and Asahi Kasei America. The other authors have no conflict of interest.

REFERENCES

1 Rhodes A, Evans LE, Alhazzani W et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit. Care Med. 2017; 45: 486–552.
2 Hifumi T, Fujishima S, Abe T et al. Prognostic factors of *Streptococcus pneumoniae* infection in adults. Am. J. Emerg. Med. 2016; 34: 202–6.
3 Takahashi T, Ubukata K, Watanabe H. Invasive infection caused by *Streptococcus dysgalactiae* subs. equisimilis: characteristics of strains and clinical features. J. Infect. Chemother. 2011; 17: 1–10.
4 Vincent JL. The coming era of precision medicine for intensive care. Crit. Care 2017; 21(Suppl 3): 314.
5 Webb SA, Kahler CM. Bench-to-bedside review: bacterial virulence and subversion of host defences. Crit. Care 2008; 12: 234.
6 Seymour CW, Gesten F, Prescott HC et al. Time to treatment and mortality during mandated emergency care for sepsis. N. Engl. J. Med. 2017; 376: 2235–44.
7 Ubukata K, Takata M, Morozumi M et al. Effects of pneumococcal conjugate vaccine on genotypic penicillin resistance and serotype changes, Japan, 2010–2017. Emerg. Infect. Dis. 2018; 24: 2010–20.
8 Morozumi M, Wajima T, Takata M, Iwata S, Ubukata K. Molecular characteristics of group B *Streptococci* isolated from adults with invasive infections in Japan. J. Clin. Microbiol. 2016; 54: 2695–700.
9 Wajima T, Morozumi M, Hanada S et al. Molecular characterization of invasive Streptococcus dysgalactiae subsp. equisimilis, Japan. Emerg. Infect. Dis. 2016; 22: 247–54.

10 Wajima T, Morozumi M, Chiba N et al. Associations of macrolide and fluoroquinolone resistance with molecular typing in Streptococcus pyogenes from invasive infections, 2010–2012. Int. J. Antimicrob. Agents 2013; 42: 447–9.

11 Barnett TC, Cole JN, Rivera-Hernandez T et al. Streptococcal toxins: role in pathogenesis and disease. Cell. Microbiol. 2015; 17: 1721–41.

12 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 1987; 40: 373–83.

13 Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit. Care Med. 2003; 31: 1250–6.

14 Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001; 286: 1754–8.

15 Singh RK, Baronia AK, Sahoo JN et al. Prospective comparison of new Japanese Association for Acute Medicine (JAAM) DIC and International Society of Thrombosis and Hemostasis (ISTH) DIC score in critically ill septic patients. Thromb. Res. 2012; 129: e119–e125.

16 Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb. Haemost. 2001; 86: 1327–30.

17 Kienast J, Juers M, Wiedermann CJ et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J. Thromb. Haemost. 2006; 4: 90–7.

18 Brooks LRK, Mias GI. Streptococcus pneumoniae’s virulence and host immunity: aging, diagnostics, and prevention. Front. Immunol. 2018; 9: 1366.

19 Harboe ZB, Thomsen RW, Riis A et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Medicine 2009; 6: e1000081.

20 Ubukata K. Serotype and antibiotic resistance of isolates from patients with invasive pneumococcal disease, Streptococcus dysgalactiae subsp. equisimilis, Streptococcus pyogenes, and Streptococcus agalactiae infections in Japan, 2018.

21 Hanada S, Iwata S, Kishi K et al. Host factors and biomarkers associated with poor outcomes in adults with invasive pneumococcal disease. PLoS ONE 2016; 11: e0147877.

22 Askim A, Mehl A, Paulsen J et al. Epidemiology and outcome of sepsis in adult patients with Streptococcus pneumoniae infection in a Norwegian county 1993–2011: an observational study. BMC Infect. Dis. 2016; 16: 223.

23 Takahashi T, Sunaoshi K, Sunakawa K, Fujishima S, Watanabe H, Ubukata K. Clinical aspects of invasive infections with Streptococcus dysgalactiae ssp. equisimilis in Japan: differences with respect to Streptococcus pyogenes and Streptococcus agalactiae infections. Clin. Microbiol. Infect. 2010; 16: 1097–103.

SUPPORTING INFORMATION

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site:

Table S1. Details of treatment (3-h bundle) of study patients.

Table S2. Comparison of treatment (3-h bundle) between virulence factors (normal versus high).

Figure S1. Cox proportional hazards regression.